Copyright
©The Author(s) 2024.
World J Clin Cases. May 26, 2024; 12(15): 2542-2550
Published online May 26, 2024. doi: 10.12998/wjcc.v12.i15.2542
Published online May 26, 2024. doi: 10.12998/wjcc.v12.i15.2542
Table 1 Clinical characteristics of 10 patients with severe pneumonia after solid organ transplantation
Recipient | Gender | Age | Type of transplanted organ | Transplant time |
1 | Male | 46 | Renal transplantation | 27 d |
2 | Male | 63 | Renal transplantation | 5 months |
3 | Female | 34 | Renal transplantation | 13 months |
4 | Male | 55 | Liver transplantation | 7 d |
5 | Male | 56 | Renal transplantation | 4 months |
6 | Female | 27 | Renal transplantation | 5 months |
7 | Female | 55 | Renal transplantation | 3 months |
8 | Male | 60 | Renal transplantation | 16 yr |
9 | Male | 27 | Renal transplantation | 4 months |
10 | Female | 40 | Renal transplantation | 7 yr |
Table 2 Treatment protocols of 10 patients with severe pneumonia after solid organ transplantation
Recipient | Treatment protocols |
1 | Carrimycin + Vancocin + Levofloxacin |
2 | Carrimycin + Amphotericin B |
3 | Carrimycin + Caspofungin + Trimethoprim-sulfamethoxazole |
4 | Carrimycin + Meropenem + Linezolid + Caspofungin |
5 | Carrimycin + Ganciclovir + Moxifloxacin + Trimethoprim-sulfamethoxazole + Peramivir |
6 | Carrimycin + Caspofungin + Piperacillin sodium and tazobactam sodium + Imipenem + Trimethoprim-sulfamethoxazole |
7 | Carrimycin + Meropenem + Azithromycin + Caspofungin |
8 | Carrimycin + Moxifloxacin + Ganciclovir + Peramivir + Imipenem + Piperacillin sodium and tazobactam sodium + Tigecycline + Linezolid + Fluconazole |
9 | Carrimycin + Caspofungin + Trimethoprim-sulfamethoxazole + Imipenem + Moxifloxacin |
10 | Carrimycin + Imipenem + Ganciclovir + Voriconazole |
Table 3 Pathogens of 10 patients with severe pneumonia after solid organ
Recipients | Pathogens |
1 | Legionnella + Corynebacterium striatum |
2 | Mucor |
3 | Pneumocystis jirovecii |
4 | Baumanii + Staphylococcus epidermidis |
5 | Pneumocystis jirovecii + Cytomegalovirus |
6 | Pneumocystis jirovecii |
7 | Haemophilus parainfluenzae + Mycoplasma |
8 | Acinetobacter + Coronavirus |
9 | Acinetobacter |
10 | Aspergillus |
Table 4 Outcomes of 10 patients with severe pneumonia after solid organ transplantation
Recipient | Outcome of transplants | Clinical outcomes |
1 | Remove | Abandoning treatment |
2 | Normal | Cure |
3 | Normal | Death |
4 | Normal | Cure |
5 | Normal | Cure |
6 | Normal | Abandoning treatment |
7 | Normal | Cure |
8 | Normal | Cure |
9 | Normal | Cure |
10 | Normal | Cure |
Table 5 Antibacterial spectrum of carrimycin found so far
Pathogens | Antimicrobial spectrum |
Gram-positive bacterium | Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus digestae, Other Streptococcus, Staphylococcus aureus, Legionella pneumophila |
Gram-negative bacterium | Haemophilus influenzae, Moraxella catarrh, Neisseria gonorrhoeae |
Anaerobe | Digestococcus, Bacteroid, Clostridium, Prevotella, Propionibacterium |
Atypical pathogens | Mycoplasma pneumoniae, Ureaplasma urealyticum, Chlamydia trachomatis, Chlamydia pneumonia |
- Citation: Cui XQ, Zhang LW, Zhao P, Feng JJ. Efficacy and safety of carrimycin in ten patients with severe pneumonia following solid organ transplantation. World J Clin Cases 2024; 12(15): 2542-2550
- URL: https://www.wjgnet.com/2307-8960/full/v12/i15/2542.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i15.2542